Front Range Pharma gets FDA OK for Long COVID trial of FRP-003
Front Range Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FRP-003, allowing it to proceed with a Phase 2 clinical trial in adults with Long COVID and persistent fatigue. The company received notification from the FDA on September 30, 2026.
Story updates
12:21:42 PM UTC
SquawkNews
Oct 6 (Reuters) — Front Range Pharmaceuticals Announces Fda Clearance To Initiate Phase 2 Trial Of Frp-003 In Long Covid Front Range Pharmaceuticals: Enrollment Is Expected To Begin In 2027 And To Take Approximately 12 Months Source text:... (Reuters.Briefs@thomsonreuters.com;)